2m 2m 2m 2m 2m 2m 2m
NovaBridge Sp ADS (NBP)
NASDAQ
$1.60+$0.01 (+0.75%)
Price as of Sep 11, 2026 7:51 PM EDT- $183.9MMarket Cap
- N/A1-Year Change
- BiotechnologyIndustry
NovaBridge Sp ADS (NBP)
$1.60+$0.01 (+0.75%)
Top Holders
Institutional
Mutual Funds
No data found
Holder | Ownership %
| Shares Held | Change (Shares, %) | Report Date |
|---|---|---|---|---|
iShares, Inc. | 10.17% | 5.1M | 0 (0.00%) | Apr 30, 2026 |
Global X Funds | 3.62% | 1.8M | 0 (0.00%) | May 31, 2026 |
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS | 2.30% | 1.2M | 0 (0.00%) | Apr 30, 2026 |
SPDR INDEX SHARES FUNDS | 1.78% | 892,500 | 0 (0.00%) | Jun 30, 2026 |
Global Macro Capital Opportunities Portfolio | 1.70% | 851,500 | 0 (0.00%) | Apr 30, 2026 |
EATON VANCE MUTUAL FUNDS TRUST | 1.34% | 672,540 | 0 (0.00%) | Apr 30, 2026 |
iSHARES TRUST | 1.18% | 591,381 | +51,863 (+8.77%) | Jun 30, 2026 |
Current Ownership Distribution
- Mutual Funds58.3M (89.91%)
- Insiders6.5M (10.09%)
- Institutions0 (0.00%)
- Other0 (0.00%)
Insider Transactions
- 10.09% (6.5M)Current InsiderOwnership (%, shares)
- 0Number of InsiderBuying (last 12 months)
- $0.00Amount of InsiderBuying (last 12 months)
- 2Number of InsiderSelling (last 12 months)
- $355,007.87Amount of InsiderSelling (last 12 months)
Insider Name & Title | Type | Date
| Transaction Value | Shares | Share Price | Shares After Transactions |
|---|---|---|---|---|---|---|
Cao Sean Wuxiong Chief Bus. Development Officer | Sell | Sep 09, 2026 | $79,903.72 | 107,978 | $0.74 | 266,467 |
Cao Sean Wuxiong Chief Bus. Development Officer | Exempt | Sep 03, 2026 | $0.00 | 102,233 | $0.00 | 306,700 |
Cao Sean Wuxiong Chief Bus. Development Officer | Exempt | Sep 03, 2026 | $0.00 | 45,320 | $0.00 | 135,960 |
Cao Sean Wuxiong Chief Bus. Development Officer | Exempt | Sep 03, 2026 | $0.00 | 235,136 | $0.00 | 270,209 |
Cao Sean Wuxiong Chief Bus. Development Officer | Exempt | Sep 03, 2026 | $0.00 | 104,236 | $0.00 | 374,445 |
Xu Cong Claire EVP, Clinical Development | Sell | Aug 31, 2026 | $2,592.78 | 3,282 | $0.79 | 304,201 |
Xu Cong Claire EVP, Clinical Development | Exempt | Aug 30, 2026 | $0.00 | 4,079 | $0.00 | 28,558 |
Xu Cong Claire EVP, Clinical Development | Exempt | Aug 30, 2026 | $0.00 | 9,382 | $0.00 | 307,483 |
Lenz Robert A. | Exempt | Aug 22, 2026 | $0.00 | 7,486 | $0.00 | 14,974 |
Lenz Robert A. | Exempt | Aug 22, 2026 | $0.00 | 17,218 | $0.00 | 17,218 |
Hagler Mark Arnold Chief Commercial Officer | Award | Jul 08, 2026 | $0.00 | 949,050 | $0.00 | 949,050 |
Gupta Srishti Chief Executive Officer | Award | Jul 06, 2026 | $0.00 | 3.0M | $0.00 | 3.0M |
Fu Wei | Award | Jun 29, 2026 | $0.00 | 725,140 | $0.00 | 725,140 |
Fu Wei | Award | Jun 29, 2026 | $0.00 | 1.1M | $0.00 | 1.1M |
Fu Wei | Award | Jun 29, 2026 | $0.00 | 1.1M | $0.00 | 1.1M |
Fu Wei | Award | Jun 29, 2026 | $0.00 | 1.0M | $0.00 | 1.0M |